Adenosine A2B receptors inhibit K+ currents and cell differentiation in cultured oligodendrocyte precursor cells and modulate sphingosine-1-phosphate signaling pathway

Biochem Pharmacol. 2020 Jul:177:113956. doi: 10.1016/j.bcp.2020.113956. Epub 2020 Apr 3.

Abstract

Oligodendrocytes are the only myelinating cells in the brain and differentiate from their progenitors (OPCs) throughout adult life. However, this process fails in demyelinating pathologies. Adenosine is emerging as an important player in OPC differentiation and we recently demonstrated that adenosine A2A receptors inhibit cell maturation by reducing voltage-dependent K+ currents. No data are available to date about the A2B receptor (A2BR) subtype. The bioactive lipid mediator sphingosine-1-phosphate (S1P) and its receptors (S1P1-5) are also crucial modulators of OPC development. An interaction between this pathway and the A2BR is reported in peripheral cells. We studied the role of A2BRs in modulating K+ currents and cell differentiation in OPC cultures and we investigated a possible interplay with S1P signaling. Our data indicate that the A2BR agonist BAY60-6583 and its new analogue P453 inhibit K+ currents in cultured OPC and the effect was prevented by the A2BR antagonist MRS1706, by K+ channel blockers and was differently modulated by the S1P analogue FTY720-P. An acute (10 min) exposure of OPCs to BAY60-6583 also increased the phosphorylated form of sphingosine kinase 1 (SphK1). A chronic (7 days) treatment with the same agonist decreased OPC differentiation whereas SphK1/2 inhibition exerted the opposite effect. Furthermore, A2BR was overexpressed during OPC differentiation, an effect prevented by the pan SphK1/2 inhibitor VPC69047. Finally, A2BR silenced cells showed increased cell maturation, decreased SphK1 expression and enhanced S1P lyase levels. We conclude that A2BRs inhibit K+ currents and cell differentiation and positively modulate S1P synthesis in cultured OPCs.

Keywords: A(2B) adenosine receptors; K(+) currents; OPC differentiation; Remyelination; Sphingosine-1-phosphate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / pharmacology
  • Animals
  • Cell Differentiation / drug effects*
  • Cells, Cultured
  • Humans
  • Lysophospholipids / pharmacology*
  • Oligodendrocyte Precursor Cells / cytology
  • Oligodendrocyte Precursor Cells / drug effects
  • Oligodendrocyte Precursor Cells / metabolism*
  • Organophosphates / pharmacology
  • Phosphorylation / drug effects
  • Phosphotransferases (Alcohol Group Acceptor) / metabolism
  • Potassium Channels / metabolism*
  • Purines / pharmacology
  • RNA Interference
  • Rats, Wistar
  • Receptor, Adenosine A2B / genetics
  • Receptor, Adenosine A2B / metabolism*
  • Signal Transduction / drug effects
  • Sphingosine / analogs & derivatives*
  • Sphingosine / pharmacology
  • Sphingosine-1-Phosphate Receptors / metabolism

Substances

  • Aminopyridines
  • BAY 60-6583
  • FTY 720P
  • Lysophospholipids
  • N-(4-acetylphenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy)acetamide
  • Organophosphates
  • Potassium Channels
  • Purines
  • Receptor, Adenosine A2B
  • Sphingosine-1-Phosphate Receptors
  • sphingosine 1-phosphate
  • Phosphotransferases (Alcohol Group Acceptor)
  • sphingosine kinase
  • Sphingosine